- Home
- SILC vs TLSA Comparison
SILC vs TLSA Comparison
Compare SILC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | TLSA |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.8M | 164.1M |
| IPO Year | 2002 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SILC | TLSA |
|---|---|---|
| Price | $42.89 | $1.57 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 111.5K | ★ 156.7K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $1.14 |
| 52 Week High | $48.92 | $2.60 |
Technical Indicators
Market Signals| Indicator | SILC | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 76.08 | 73.19 |
| Support Level | $16.10 | $1.52 |
| Resistance Level | N/A | $1.60 |
| Average True Range (ATR) | 3.72 | 0.11 |
| MACD | 1.00 | 0.04 |
| Stochastic Oscillator | 78.30 | 86.67 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.